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Introduction {#sec008}
============

Respiratory tract infections (RTIs) are the most common diagnosis in febrile children, and the most common reason for antibiotic prescription in children \[[@pmed.1003034.ref001]\]. In children under 5 years, most lower RTIs are viral \[[@pmed.1003034.ref002]\]. Although mortality caused by lower RTIs has decreased significantly over the past decades (currently 1.7 per 100,000 people in Western Europe) \[[@pmed.1003034.ref003]\], antimicrobial resistance due to unnecessary antibiotic prescription is increasing \[[@pmed.1003034.ref004]\]. High variability in antibiotic prescription in children with RTIs in primary as well as hospital care throughout Europe highlights the need for better targeting of antibiotic prescriptions in this patient group \[[@pmed.1003034.ref001],[@pmed.1003034.ref005],[@pmed.1003034.ref006]\].

One of the main challenges when attempting to safely reduce antibiotic prescriptions for lower RTIs in children is the absence of a gold standard for the diagnosis of bacterial pneumonia. Routine chest X-rays are no longer recommended for the differentiation between bacterial and viral causes, and treatment decisions are mostly based on clinical findings \[[@pmed.1003034.ref007],[@pmed.1003034.ref008]\]. Ongoing research into new biomarkers has not yet provided a new gold standard for clinical practice in the emergency department (ED) \[[@pmed.1003034.ref009]--[@pmed.1003034.ref011]\]. In the absence of a gold standard for diagnosing bacterial pneumonia, we need to improve the clinical detection rate of those children who may benefit most from antibiotic treatment of bacterial pneumonia. Clinical prediction models combining clinical characteristics and biomarkers may improve the identification of children who will benefit from antibiotic treatment for community-acquired pneumonia, but they are not used as decision rules in clinical practice \[[@pmed.1003034.ref012],[@pmed.1003034.ref013]\]. The Feverkidstool is a clinical prediction model combining clinical characteristics and C-reactive protein (CRP) to predict the risk of bacterial pneumonia and other serious bacterial infections in children. The model was derived in the ED setting in The Netherlands, and its diagnostic accuracy has been proven in external validation studies in The Netherlands and the United Kingdom \[[@pmed.1003034.ref013],[@pmed.1003034.ref014]\].

In this study we evaluated the impact of the Feverkidstool on clinical practice, as a last step in the development of a prediction model \[[@pmed.1003034.ref015]\]. We translated the Feverkidstool into a decision rule with pre-specified decision thresholds to guide antibiotic treatment for lower RTIs. The primary objective of this study was to safely reduce antibiotic prescription in children under 5 years with suspected lower RTI at the ED, by withholding antibiotics in children at low or intermediate risk of bacterial pneumonia, as predicted by the Feverkidstool.

Methods {#sec009}
=======

Study design {#sec010}
------------

We performed a stepped-wedge cluster randomised trial with sequential implementation of a treatment strategy for antibiotic prescription based on a clinical decision rule (hereafter called 'decision rule') in febrile children with suspected lower RTI in the ED. Randomisation at cluster level was chosen to avoid contamination of the intervention effect to control patients. The stepped-wedge design was preferred as, in general, smaller sample sizes are needed than in conventional cluster randomised trials. Because clusters act as their own controls, the intervention effect can be estimated from both between and within cluster comparisons. The sequential implementation of the intervention was deemed superior to a conventional before--after design, given the incorporation of time effects \[[@pmed.1003034.ref016]\]. We performed the trial in 8 clusters (hospitals) between 1 January 2016 and 30 September 2018 in The Netherlands. By design, the trial consisted of 2 phases: a pre-intervention phase, when usual care was provided, and an intervention phase, wherein care was provided according to our intervention (diagram of trial design in [Fig 1](#pmed.1003034.g001){ref-type="fig"}). A cluster consisted of 1 hospital that was randomised to 1 sequence of treatment. Each hospital was randomised to 1 sequence of treatment, resulting in 8 sequences. The period when all hospitals still performed usual care (the baseline period) was followed by a rollout period, during which the hospitals switched sequentially to the intervention (antibiotic prescription guided by the decision rule). At intervals of 4 weeks, hospitals were randomised to start the intervention between 28 August 2017 and 12 March 2018. This timing was chosen to take the seasonality of RTIs into account, as most eligible patients were expected during autumn and winter. Given the short duration of illness, the patients included in the different time periods were different people. The original and the final study protocol are available as [S1 Text](#pmed.1003034.s006){ref-type="supplementary-material"} and [S2 Text](#pmed.1003034.s007){ref-type="supplementary-material"}. The trial was approved by the ethics committee of Erasmus MC (MEC-2014-332) and by the participating hospitals. Written informed consent was obtained from the parents of all participants by the treating physician, in both phases of the trial. In the pre-intervention phase, this consent concerned the use of clinical data and performance of follow-up; in the intervention phase, it also concerned the use of the Feverkidstool to guide treatment decisions. Consent was obtained before calculating the predicted risk of the child. The trial was registered in the Netherlands Trial Register (NTR) (NTR5326). As reported in the NTR, 1 cluster was added during the pre-intervention period, to ensure sufficient inclusions. Interim analysis after the first year of data collection (but before implementation of the intervention) showed substantially higher antibiotic prescription rates than anticipated. Based on the distribution of risks and actual antibiotic prescription rates during the pre-intervention period, the target sample size was adjusted from 1,100 to 900 children, which is also reported in the NTR. No other important methodological changes were made after the start of the trial. The study was reported according to the CONSORT guideline for clinical trials and the extension for stepped-wedge cluster randomised trials ([S1 Table](#pmed.1003034.s001){ref-type="supplementary-material"}).

![Design of the trial.\
ED, emergency department.](pmed.1003034.g001){#pmed.1003034.g001}

Participants {#sec011}
------------

We included children aged 1--60 months that presented with fever (reported by parents or measured as \>38.5° C at the ED) and cough or dyspnoea as symptoms of potential lower RTI at the EDs of 8 hospitals in The Netherlands. This target population included children with all different risk profiles, since at presentation in the ED their risk profile was unknown. We excluded children at increased risk of a complicated course: children with relevant comorbidities, antibiotic use in the week prior to ED visit, amoxicillin allergies, another identifiable infectious focus (cutaneous, otitis media, tonsillitis), or signs of complicated pneumonia at presentation (oxygen saturation \< 85%, respiratory insufficiency, empyema, sepsis). Relevant comorbidities were immunodeficiency, congenital heart defect, chronic pulmonary disease, multiple handicaps, and prematurity (born before the gestational age of 32 weeks and aged \<1 year at time of presentation). Individual participants were included in the clusters by continuous recruitment by the treating physician in the ED. We included 8 hospitals in 6 cities of the southwest and central area of The Netherlands (a) where paediatricians were responsible for the children presenting at the ED, (b) with varying ED sizes (range 500--13,000 annual paediatric ED admissions), (c) from diverse geographic and demographic regions (inner-city and mixed rural/urban), and (d) of different hospital types (tertiary and general). Hospitals were separated geographically, with no exchange of staff. The hospitals were recruited by the principal investigator (RO).

Randomisation and blinding {#sec012}
--------------------------

Randomisation of sequences of treatment was performed in July 2017 (after recruitment of all 8 clusters) by a statistician using computer randomisation. The statistician was involved as an advisor in the trial and was based at Erasmus MC. He knew the names of the other participating centres at randomisation, but had no further knowledge of these hospitals or relation to the local researchers. Since 2 hospitals started in August 2017 with the pre-intervention phase due to logistical reasons, these hospitals were randomised to start the intervention after time period 3 ([Fig 1](#pmed.1003034.g001){ref-type="fig"}). This was accounted for in the original randomisation prior to the rollout period. The trial could not be blinded, because the intervention was the implementation and use of a decision rule by clinicians in the ED, including treatment advice based on the risk score that had to be calculated for each child.

Intervention {#sec013}
------------

During the pre-intervention phase, all children received usual care. Usual care consisted of triage by a nurse, including the routine measurement of vital signs, followed by a clinical assessment and initiation of therapy by a physician, according to the Dutch and NICE guidelines for febrile children \[[@pmed.1003034.ref017],[@pmed.1003034.ref018]\]. Additional diagnostics were performed at the discretion of the treating physician. CRP testing was often done as part of usual care, but without specific thresholds for decision-making. Other blood tests or chest X-rays were not routinely performed in children with suspected lower RTI, in line with the Dutch guideline, which is based on the British Thoracic Society guideline for the management of children with community-acquired pneumonia \[[@pmed.1003034.ref008]\]. During usual care, antibiotics were prescribed at the discretion of the treating physician. Amoxicillin was usually prescribed as first-line treatment for community-acquired pneumonia \[[@pmed.1003034.ref008]\].

During the intervention phase, a validated clinical prediction model (Feverkidstool) was implemented as a decision rule guiding antibiotic prescription at the cluster level \[[@pmed.1003034.ref012],[@pmed.1003034.ref013]\]. We predefined decision thresholds that would guide antibiotic treatment decisions, balancing positive and negative likelihood ratios and the consequences of over- and undertreatment \[[@pmed.1003034.ref012],[@pmed.1003034.ref019]\]. The intervention was a decision-rule-based treatment strategy for all children with suspected lower RTI in the ED, with a differential effect on risk groups. In children with a low (≤3%) or intermediate (4%--10%) predicted risk of bacterial pneumonia, antibiotics were withheld. In children with a high predicted risk (\>10%), usual care was provided, i.e., antibiotics were prescribed at the discretion of the physician. The Feverkidstool included the following predictors: age in years, sex, duration of fever in days, ill appearance (yes/no), chest wall retractions (yes/no), capillary refill time in seconds, hypoxia (oxygen saturation \< 94%), tachypnoea (based on Advanced Paediatric Life Support guideline), tachycardia (idem), temperature in degrees Celsius, and CRP in mg/l. Ill appearance was based on the judgment of the treating clinician. Although ill appearance was not defined by specific criteria, in the development and validation of the Feverkidstool this characteristic appeared to be valid and consistent among different populations \[[@pmed.1003034.ref012]\]. More details about the development of the Feverkidstool have been published previously \[[@pmed.1003034.ref012]\]. The tool was available to all treating physicians as an online digital calculator. The individual predicted risk was calculated after the physician's clinical assessment of the child and CRP testing, but before the treatment decision was made. During both phases of the study, a structured follow-up via telephone was performed 7 days after the ED visit. During the intervention phase, children with an intermediate or high predicted risk received an extra follow-up call 2 days after the ED visit to timely identify potential deterioration of the patient. When children were still hospitalised at those time points, the follow-up information was collected directly from the parents and the patient's electronic health record.

Outcomes {#sec014}
--------

Primary outcomes were antibiotic prescription at ED discharge (yes/no) and strategy failure within 7 days after the initial ED visit (yes/no). Since the decision rule should not impact patient outcomes negatively (complying with our aim 'to safely reduce antibiotic prescriptions'), we viewed antibiotic prescription and strategy failure as equally important co-primary outcomes. Strategy failure was a composite outcome, based on the follow-up on day 7 and defined as secondary hospitalisation (i.e., hospitalisation during follow-up, after the initial discharge), secondary or switched antibiotic prescription (during follow-up), oxygen dependency or fever up to day 7, or the development of complications. Since there is no single and objective measure of failure of antibiotic treatment strategy, we used this predefined composite outcome for strategy failure. This outcome was chosen to cover different aspects of strategy failure that are important in clinical practice and may be related to the initial treatment strategy at the ED \[[@pmed.1003034.ref020]\]. It includes changes in the treatment strategy for the child (secondary or switched antibiotic treatment and secondary hospitalisation) as well as signs of prolonged or complicated disease (oxygen dependency or fever up to day 7 and complications). Changes in treatment strategy during follow-up were made without specific recommendations in the study protocol. Reasons for switching antibiotic prescription were not systematically recorded. Switching of antibiotics due to adverse drug reaction was considered a strategy failure. We used a short follow-up period of 1 week, assuming that a secondary hospitalisation within this time frame was related to the respiratory illness. All secondary prescriptions and secondary hospitalisations were considered a strategy failure. Secondary outcomes were the level of compliance to the intervention and the number of complications. Compliance was defined as the number of children in whom the Feverkidstool was calculated and who were treated according to the decision rule out of the total number of children included during the intervention phase. Complications were defined as the presence of pleural empyema, parapneumonic effusion (any size), pulmonary abscess, or respiratory insufficiency (need for mechanical ventilation) by day 7. No changes were made to the outcomes after the trial commenced.

Statistical methods {#sec015}
-------------------

### Sample size {#sec016}

We calculated the needed sample size for the 2 co-primary outcomes based on methods by Hussey and Hughes, without accounting for multiple testing \[[@pmed.1003034.ref016]\]. We based our sample size calculation on the complete target population of children with suspected lower RTI in the ED, including all risk groups. Based on previous studies \[[@pmed.1003034.ref014]\], we assumed that 50% of the population would be at low risk, 30% at intermediate risk, and 20% at high risk, with antibiotic prescription rates of 35% (in the low-risk group), 40% (intermediate-risk group), and 85% (high-risk group). The decision rule was expected to affect risk groups differently: we estimated no difference in antibiotic prescription in the high-risk patients, and a reduction of 10--15 percentage points in the low-risk and intermediate-risk patients, leading to an overall reduction of antibiotic prescriptions of 10 percentage points. The intracluster correlation coefficient (ICC) was unknown, but we assumed that a power of 90% at independency (i.e., no correlation between clusters, ICC of 0) would result in a power of 80% or more in multilevel analysis. We assumed different cluster sizes (small, intermediate, and large clusters) and 3-level seasonal variation in inclusion of patients. All assumptions are listed in [S3 Text](#pmed.1003034.s008){ref-type="supplementary-material"}. Based on these assumptions, we originally estimated a needed sample size of 1,100 children with a suspected lower RTI. Interim analysis of inclusions during the first year showed a higher baseline prescription rate than was assumed. An interim power calculation based on this rate resulted in a needed sample size of 900 children to show superiority of the decision rule for antibiotic prescription with a power of 0.9 and an alpha of 0.05 (see [S1 Text](#pmed.1003034.s006){ref-type="supplementary-material"}). This number was also sensitive to show non-inferiority of the intervention in terms of strategy failure with a non-inferiority margin of 5%: It could detect a 2-fold increase of secondary hospitalisation (the part of strategy failure with available baseline data: 5% at the time of original sample size calculation) with a power of 0.8 and alpha of 0.05. The interim power analysis was performed before introduction of the intervention, so it was blinded to the outcomes of the trial \[[@pmed.1003034.ref021]\].

### Primary analyses {#sec017}

We used multilevel generalised linear mixed models to calculate the impact of the intervention on our 2 primary outcomes: antibiotic prescription and strategy failure. Hospitals were added as a random effect to take clustering at the hospital level into account. Time period (1--9) was added as a fixed effect to adjust for a secular time trend introduced by the design of the study \[[@pmed.1003034.ref022]\]. In the primary analyses we adjusted for pre-specified factors that may have influenced participation in the study or compliance to the protocol, i.e., age, sex, fever duration, season, and ill appearance. We tested the linearity of the associations between continuous predictors and outcomes. Detailed models can be found in the pre-specified statistical analysis plan ([S4 Text](#pmed.1003034.s009){ref-type="supplementary-material"}). We performed an intention-to-treat analysis, i.e., the intervention population contained all of the children in the intervention phase, including those cases where doctors did not comply to the protocol ([Fig 2](#pmed.1003034.g002){ref-type="fig"}). We analysed the outcome strategy failure in all children with follow-up information on strategy failure available. We also performed per-protocol analyses to evaluate the impact of the decision rule on the primary outcomes in cases of compliance to the protocol. For this per-protocol analysis, the intervention group consisted only of those children in whom the physicians complied to the protocol ([Fig 2](#pmed.1003034.g002){ref-type="fig"}).

![Flowchart of inclusion.\
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### Secondary analyses {#sec018}

We report the level of compliance to the intervention and the number of complications during both phases of the study.

### Pre-specified sensitivity analyses {#sec019}

We pre-specified 4 sensitivity analyses. First, to estimate the effect of the imputation of missing covariates on our primary analyses, we planned a sensitivity analysis on all covariates with \>10% missing values, using different assumptions. Second, to evaluate the effect of loss to follow-up on the outcome strategy failure, we planned a sensitivity analysis assuming that (a) strategy failure occurred in all children with missing follow-up or (b) strategy failure occurred in none of those children. Third, to evaluate the effect of the longer baseline and post-rollout periods, we performed a sensitivity analysis of the primary outcome that only used data from 4 weeks before until 4 weeks after the rollout period (31 July 2017--8 April 2018), resulting in 9 time periods of equal length. Fourth, the level of routine measurement of CRP in the pre-intervention phase differed between hospitals. To adjust for this factor, we performed a sensitivity analysis on the data of only those hospitals that did perform routine CRP measurement in the population throughout both phases of the study.

### Exploratory subgroup analysis {#sec020}

We performed an exploratory subgroup analysis of the primary outcomes in the different risk groups. Because our intervention was to withhold antibiotics in children at low or intermediate risk of bacterial pneumonia, we expected the most effect on primary outcomes in those risk groups. However, our study was not powered for subgroup analyses, so we performed these post hoc as exploratory analyses, to generate hypotheses for the interpretation of the overall primary results. We analysed the primary outcomes in the low- and intermediate-risk groups combined (≤10%) versus the high predicted risk (\>10%) group, testing for a difference in effect using an interaction term (intervention × risk group). For these analyses we used the data of all children in whom the Feverkidstool---and thereby the risk group---could be calculated (complete case analysis), because we could not select subgroups based on imputed data. We did not perform other post hoc analyses.

### Missing data {#sec021}

We assumed missing data to be missing at random, and handled missing covariates by means of multiple imputation using the mice package in R (version 3.3.4). The imputation model included all of the variables needed for the primary and sensitivity analyses, as well as additional information on diagnosis, treatment, disposition, and follow-up. Outcome variables (antibiotic prescription and strategy failure) were not imputed, except for the sensitivity analysis evaluating the effect of loss to follow-up on the outcome strategy failure. In this sensitivity analysis we used single imputation only for the outcome variable strategy failure, assuming 100% failure if the variable was missing in one dataset versus 0% failure in another dataset. We did not impute predicted risk for the selection of risk groups in the exploratory analyses. If parents could not be reached for a follow-up on day 7 via telephone, follow-up information was retrieved from the child's electronic health record.

Results {#sec022}
=======

Recruitment {#sec023}
-----------

The baseline period ran from 1 January 2016 to 27 August 2017, and from 28 August 2017 to 12 March 2018 (the rollout period) the hospitals started the intervention phase one by one every 4 weeks; we collected data until 30 September 2018, when the target sample size was reached ([Fig 1](#pmed.1003034.g001){ref-type="fig"}). All hospitals adhered to their allocated sequence of treatment and the planned rollout dates. All hospitals that were assessed for eligibility were recruited (*n =* 8); after recruitment, all 8 were randomised to a treatment sequence and included in the analyses ([Fig 1](#pmed.1003034.g001){ref-type="fig"}). In total, 1,704 children were assessed for eligibility, and 1,027 children included in the trial (375 not included in the pre-intervention phase, 302 in the intervention phase). Of the included children, 28 children met the exclusion criteria, leaving 999 children for analyses of the primary outcome antibiotic prescription. Of these, 46 (5%) were lost to follow-up. Because the outcome strategy failure was based on follow-up, and because we did not impute outcome variables, the remaining 953 children were included in the analyses for strategy failure. Details of patient flow in the trial can be found in [Fig 2](#pmed.1003034.g002){ref-type="fig"}, and details of inclusion at the cluster level in [Fig 1](#pmed.1003034.g001){ref-type="fig"}. The main reason for non-inclusion of patients was that the ED was too busy to enrol patients in the trial. The children not included were generally less severely ill, reflected by a lower urgency at triage, fewer antibiotic prescriptions, and fewer hospitalisations ([S2 Table](#pmed.1003034.s002){ref-type="supplementary-material"}).

Baseline data {#sec024}
-------------

The majority of children were male (*n =* 611, 61%), their median age was 17 months (interquartile range \[IQR\] 9 to 30), and most were referred to the ED by a general practitioner ([Table 1](#pmed.1003034.t001){ref-type="table"}). One-third of children appeared ill upon ED presentation, and the majority were tachycardic or tachypnoeic or exhibited chest wall retractions. Half of children were hospitalised, for a median duration of 3 days, mainly for oxygen therapy. During the pre-intervention phase, CRP testing was not routinely performed in all children, depending on differences in usual care in the participating hospitals. One hospital was a tertiary care centre; the others were general hospitals (see [S3 Table](#pmed.1003034.s003){ref-type="supplementary-material"} for baseline characteristics per hospital). Annual admissions to the paediatric EDs ranged from 500 to 13,000 ([Fig 1](#pmed.1003034.g001){ref-type="fig"}).

10.1371/journal.pmed.1003034.t001

###### Baseline characteristics of the study population.

![](pmed.1003034.t001){#pmed.1003034.t001g}

  ---------------------------------------------------------------------------------------------
                                                        Pre-intervention\   Intervention\
                                                        *n* = 597           *n* = 402
  ----------------------------------------------------- ------------------- -------------------
  **General characteristics**                                                

  Male sex                                              364/597 (61%)       246/402 (61%)

  Age in months                                         17 (9--30)          17 (9--31)

  Season                                                                    

      Spring                                            76/597 (13%)        114/402 (28%)

      Summer                                            55/597 (9%)         49/402 (12%)

      Autumn                                            198/597 (33%)       88/402 (22%)

      Winter                                            268/597 (45%)       151/402 (38%)

  Way of referral to ED                                                     

      General practitioner                              441/578 (76%)       295/379 (78%)

      Self                                              66/578 (11%)        45/379 (12%)

      Other healthcare professional                     71/578 (12%)        39/379 (10%)

  Triage level                                                              

      Immediate or very urgent                          306/506 (60%)       182/332 (55%)

      Urgent                                            146/506 (29%)       121/332 (36%)

      Standard or non-urgent                            54/506 (11%)        29/332 (9%)

  **Signs and symptoms**                                                     

  Ill appearance[\*](#t001fn002){ref-type="table-fn"}   220/572 (38%)       138/400 (35%)

  Duration of fever in days                             2 (1--4)            2 (1--4)

  Temperature in°C                                      38.8 (38.1--39.5)   38.9 (38.1--39.5)

  Hypoxia (oxygen saturation \< 94%)                    144/595 (24%)       74/401 (18%)

  Tachycardia                                           416/595 (70%)       274/402 (68%)

  Tachypnoea                                            487/581 (84%)       315/402 (78%)

  Retractions                                           376/578 (65%)       237/401 (59%)

  Dyspnoea                                              432/581 (74%)       290/402 (72%)

  Wheezing                                              233/565 (41%)       132/395 (33%)

  Prolonged capillary refill (≥2 seconds)               96/553 (17%)        19/401 (5%)

  **Management**                                                             

  C-reactive protein test performed                     372/597 (62%)       380/402 (95%)

  C-reactive protein in mg/l                            19 (7--44)          18 (7--38)

  Chest X-ray performed                                 109/597 (18%)       49/402 (12%)

  Discharge diagnosis                                                       

      Pneumonia                                         204/594 (34%)       110/401 (27%)

      Bronchiolitis                                     117/594 (20%)       79/401 (20%)

      Upper RTI                                         197/594 (33%)       156/401 (39%)

      Viral induced wheeze                              69/594 (12%)        49/401 (12%)

      Other                                             7/594 (1%)          7/401 (2%)

  Hospitalisation                                       329/597 (55%)       181/402 (45%)

  Length of stay in days                                3 (2--5)            3 (2--5)

  Reason for hospitalisation                                                

      Oxygen therapy                                    235/329 (71%)       132/180 (73%)

      Intake of antibiotics                             8/329 (2%)          2/180 (1%)

      Nebuliser bronchodilator                          10/329 (3%)         4/180 (2%)

      Monitoring                                        69/329 (21%)        39/180 (22%)

      Other                                             7/329 (2%)          3/180 (2%)

  Type of antibiotic prescribed                                             

      Amoxicillin                                       152/179 (85%)       84/101 (83%)

      Amoxicillin/clavulanic acid                       8/179 (4%)          6/101 (6%)

      Azithromycin                                      17/179 (9%)         4/101 (4%)

      Cefuroxime                                        2/179 (1%)          1/101 (1%)

      Other                                             0/179 (0%)          5/101 (5%)

      Unknown                                           0/179 (0%)          1/101 (1%)
  ---------------------------------------------------------------------------------------------

Categorical variables are presented as number/total (percentage), and continuous variables as median (interquartile range). The pre-intervention and intervention populations in a stepped-wedge trial cannot be directly compared, but should be adjusted for a secular time trend \[[@pmed.1003034.ref022]\].

\*Based on physician's judgment (yes/no).

ED, emergency department; RTI, respiratory tract infection.

Primary and sensitivity analyses {#sec025}
--------------------------------

Overall antibiotic prescription was not reduced in the intervention phase (30% versus 25%; adjusted odds ratio \[aOR\] 1.07, 95% CI 0.57 to 2.01, *p =* 0.75; [Table 2](#pmed.1003034.t002){ref-type="table"}). Antibiotic prescription rates per hospital and per time period are provided in [S4 Table](#pmed.1003034.s004){ref-type="supplementary-material"}. Strategy failure decreased from 23% in the pre-intervention phase to 16% in the intervention phase (aOR 0.53, 95% CI 0.32 to 0.88, *p =* 0.01). The per-protocol analysis gave similar results as the intention-to-treat analysis, showing that non-compliance to the decision rule did not influence the observed effect on the primary outcomes. Also the results of the sensitivity analysis with truncated baseline and post-rollout periods were comparable to the analyses on the whole population ([Table 2](#pmed.1003034.t002){ref-type="table"}). Two pre-planned sensitivity analyses were not needed: adjusting for missing covariates and adjusting for level of CRP measurement in pre-intervention phase. All covariates for the primary analyses had less than 10% missing values ([Table 1](#pmed.1003034.t001){ref-type="table"}), so we assume that no bias was introduced by multiple imputation. There was no difference in the level of CRP measurement between hospitals that performed CRP routinely during the pre-intervention phase and those that did not. Loss to follow-up had no effect on the outcome strategy failure, as shown by the sensitivity analyses that assumed different outcomes for those lost to follow-up ([Table 2](#pmed.1003034.t002){ref-type="table"}). Secondary antibiotic prescription was the most frequent reason for strategy failure ([Table 2](#pmed.1003034.t002){ref-type="table"}).

10.1371/journal.pmed.1003034.t002

###### Antibiotic prescription and strategy failure.

![](pmed.1003034.t002){#pmed.1003034.t002g}

  Analysis and outcome                                                                Number/total (percentage)   Unadjusted      Adjusted                                                   
  ----------------------------------------------------------------------------------- --------------------------- --------------- ----------------------- ---------- ----------------------- ----------
  **Primary analyses**                                                                                                                                                                       
  Intention-to-treat population                                                                                                                                                              
      Antibiotic prescription                                                         179/597 (30%)               101/402 (25%)   1.06 (0.61--1.85)       0.84       1.07 (0.57--2.01)       0.75
      Strategy failure                                                                131/572 (23%)               61/381 (16%)    **0.56 (0.34--0.93)**   **0.02**   **0.53 (0.32--0.88)**   **0.01**
  Per-protocol population                                                                                                                                                                    
      Antibiotic prescription                                                         179/597 (30%)               83/359 (23%)    0.89 (0.5--1.61)        0.71       0.96 (0.49--1.88)       0.92
      Strategy failure                                                                131/572 (23%)               57/340 (17%)    **0.60 (0.36--1.00)**   **0.05**   **0.56 (0.34--0.93)**   **0.03**
  **Sensitivity analyses**                                                                                                                                                                    
  Truncated baseline and post-rollout periods[^§^](#t002fn005){ref-type="table-fn"}                                                                                                          
      Antibiotic prescription                                                         66/276 (24%)                64/279 (23%)    0.81 (0.45--1.46)       0.48       0.71 (0.38--1.32)       0.27
      Strategy failure                                                                58/261 (22%)                46/269 (17%)    **0.57 (0.35--0.94)**   **0.03**   **0.54 (0.33--0.90)**   **0.02**
  Strategy failure, including missing values                                                                                                                                                 
      Assumption missing = failure                                                    156/597 (26%)               82/402 (20%)    **0.56 (0.36--0.88)**   **0.01**   **0.55 (0.35--0.87)**   **0.01**
      Assumption missing = no failure                                                 131/597 (22%)               61/402 (15%)    **0.59 (0.36--0.96)**   **0.03**   **0.56 (0.34--0.91)**   **0.02**
  **Secondary analyses**                                                                                                                                                                      
  Compliance (Feverkidstool calculated and patient treated according to advice)       NA                          359/402 (89%)                                                              
  Complications[^¶^](#t002fn006){ref-type="table-fn"}                                 1/572 (0.1%)                1/381 (0.2%)                                                               
  **Strategy failure: reasons**                                                                                                                                                              
  Secondary antibiotic prescription                                                   45/572 (8%)                 29/381 (8%)                                                                
  Changed antibiotics during follow-up                                                14/572 (2%)                 5/381 (1%)                                                                 
  Secondary hospitalisation[\*\*](#t002fn007){ref-type="table-fn"}                    16/572 (3%)                 13/381 (3%)                                                                
  Oxygen need at day 7                                                                9/572 (2%)                  1/381 (0.2%)                                                               
  Fever at day 7                                                                      47/572 (8%)                 13/381 (3%)                                                                

Bolding indicates statistical significance.

\*Main model: clustered by hospital, adjusted for time period. Time-adjusted intracluster correlation coefficient for antibiotic prescription = 0.04, for strategy failure = 0.

^†^*p*-Values based on multivariable logistic regression.

^‡^Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.

^§^Using data from 4 weeks before until 4 weeks after the rollout period, resulting in 9 time periods of equal length, truncating the prolonged baseline and post-rollout periods.

^¶^Complications were 1 admission to intensive care unit in the pre-intervention phase and 1 pleural empyema in the intervention phase (both unrelated to study intervention).

\*\*Including 1 admission to the intensive care unit in the pre-intervention group.

NA, not applicable.

Secondary analyses {#sec026}
------------------

In 43/402 (11%) cases, the clinician was not compliant with the decision rule ([Table 2](#pmed.1003034.t002){ref-type="table"}). Two complications occurred during the trial: in the pre-intervention phase 1 child was admitted to the intensive care unit during follow-up for mechanical ventilation; in the intervention phase 1 child developed pleural empyema at day 10. Both complications were unrelated to the study intervention, since both patients treated with antibiotics at the first ED visit.

Exploratory subgroup analysis: Risk groups {#sec027}
------------------------------------------

We had complete information on all Feverkidstool predictors in 331/597 (55%) of the children in the pre-intervention phase. CRP was the most frequent missing variable (225/597, 38%). The complete case analysis showed that the effect of the decision rule was different across risk groups (*p \<* 0.01; [Table 3](#pmed.1003034.t003){ref-type="table"}). Antibiotic prescription was lower in the low and intermediate risk groups combined (≤10% predicted risk) during the intervention phase, whereas in the high-risk group prescription rates were higher, but not statistically significantly so. The reduction in strategy failure was observed in the high-risk group ([Table 3](#pmed.1003034.t003){ref-type="table"}), mainly via fewer secondary antibiotic prescriptions and less frequent fever at day 7 ([S5 Table](#pmed.1003034.s005){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003034.t003

###### Exploratory subgroup analysis on complete cases (*n* = 705)[\*](#t003fn002){ref-type="table-fn"}.

![](pmed.1003034.t003){#pmed.1003034.t003g}

  Subgroup analysis[^†^](#t003fn003){ref-type="table-fn"}   Number/total (percentage)   Unadjusted     Adjusted                                                   
  --------------------------------------------------------- --------------------------- -------------- ----------------------- ---------- ----------------------- ----------
  **Low/intermediate-risk population (\<10%)**                                                                                                                    
      Antibiotic prescription                               29/172 (17%)                15/234 (6%)    **0.37 (0.15--0.94)**   **0.04**   **0.31 (0.12--0.81)**   **0.02**
      Strategy failure                                      29/159 (18%)                39/218 (18%)   0.91 (0.43--1.90)       0.80       0.88 (0.42--1.87)       0.75
  **High-risk population (\>10%)**                                                                                                                                
      Antibiotic prescription                               75/159 (47%)                83/140 (59%)   2.04 (0.84--4.94)       0.11       2.28 (0.84--6.17)       0.09
      Strategy failure                                      42/155 (27%)                20/136 (15%)   0.45 (0.18--1.15)       0.10       **0.37 (0.14--0.99)**   **0.05**

Bolding indicates statistical significance.

\*331/597 (55%) cases were complete in the pre-intervention population, of which 172/331 (52%) were in the low or intermediate risk group (*n =* 91 low risk; *n =* 81 intermediate risk); 374/402 (93%) cases were complete in the intervention population, of which 234/374 (63%) were in the low or intermediate risk group (*n =* 115 low risk; *n =* 119 intermediate risk).

^†^Interaction term intervention × risk group *p \<* 0.01.

^‡^Main model: clustered by hospital, adjusted for time period.

^§^*p*-Values based on multivariable logistic regression.

^¶^Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.

Discussion {#sec028}
==========

We showed that a clinical decision rule did not reduce overall antibiotic prescription in children with suspected lower RTI in the ED, but that it did reduce strategy failure. Exploratory subgroup analyses showed that the intervention influenced the outcomes in the risk groups differently.

Our primary aim was to safely reduce antibiotic prescription in children under 5 years with suspected lower RTI at the ED. We hypothesized that introducing a decision rule as an intervention would safely reduce antibiotic prescriptions in these children. This target population included children with all different risk profiles, since at presentation in the ED their risk was unknown. The first primary endpoint of reducing antibiotic prescription was not met. The other primary endpoint of not increasing strategy failure was met. Moreover, we observed a reduction in strategy failure, suggesting that antibiotic prescriptions were more appropriately targeted to children who benefited from antibiotics. This additional hypothesis was supported by our exploratory subgroup analysis, showing a safe reduction in antibiotic treatments in the low/intermediate-risk group and a (non-significant) increase of prescriptions and a reduction of strategy failures in the high-risk children. This suggests a shift in antibiotic prescriptions from the low/intermediate-risk children towards the high-risk children who had more clinical benefit from the antibiotics. Our power calculation was based on the complete target population of children with suspected lower RTI, assuming a distribution of risk based on previous research. Post hoc sensitivity analysis of the sample size calculation showed that our study was sufficiently powered (power of 0.8), also when accounting for clustering at varying ICC values (range 0.01--0.26) and adjusted for multiple testing. However, we observed a smaller proportion of low/intermediate-risk children in our study population than expected. The shift in antibiotic prescriptions towards high-risk children and the observed smaller proportion of low/intermediate-risk children in our study may explain why we did not detect an overall reduction in antibiotic prescription. However, it must be noted that this finding was based on complete case analysis only and that our study was not powered for subgroup analyses.

We used a composite outcome to define strategy failure. Composite outcomes can be problematic, if the effect of the intervention is mainly driven by less important components \[[@pmed.1003034.ref020]\]. In our study we found that a reduction in secondary antibiotic prescriptions was the main component of the reduction in strategy failures in the high-risk children and in those in whom we could not calculate the risk score ([S5 Table](#pmed.1003034.s005){ref-type="supplementary-material"}). In low/intermediate-risk children, secondary prescription slightly increased, but without increasing oxygen need or fever at day 7 (proxies for disease severity). There was no increase in complications during the intervention phase. These observations show that our intervention was safe, with reduced strategy failure on clinically important outcomes.

In this trial we used a threshold of 10% to define low/intermediate- versus high-risk patients, based on previous observed diagnostic performance \[[@pmed.1003034.ref012]\], which appeared to be safe. Given the relatively low observed antibiotic prescription rate in the high-risk group, a higher threshold may also be reasonable and more specific, but may carry a risk of increasing strategy failure. These considerations highlight the difficulty in obtaining the optimal balance between reducing overuse of antibiotics (important from a public health perspective) and at the same time striving for the best clinical outcomes for the individual patient \[[@pmed.1003034.ref019]\].

Other impact studies of decision rules for infections in children that combine biomarkers and clinical characteristics are scarce. In a previous impact study, the Feverkidstool was used as a decision rule to guide diagnostic decisions in febrile children in a tertiary hospital. This resulted in a more standardised diagnostic approach, but did not improve the study's secondary patient outcomes, namely antibiotic treatment and hospitalisation \[[@pmed.1003034.ref014]\]. A study of Lab-score (a decision rule combining biomarkers) failed to prove its impact on antibiotic prescription in infants with fever without source \[[@pmed.1003034.ref023]\]. Two studies have been reported in non-Western countries on the impact of decision rules on antibiotic prescription \[[@pmed.1003034.ref024],[@pmed.1003034.ref025]\]. A bacterial pneumonia score reduced antibiotic prescription without increasing treatment failure \[[@pmed.1003034.ref024]\], but requires neutrophil testing and a chest X-ray, both of which are not recommended routinely for the management of children with suspected lower RTIs. In Tanzania an algorithm including clinical features, CRP, and procalcitonin (PCT) reduced antibiotic prescription from 94.9% to 11.5% and improved clinical outcomes in febrile children in primary care \[[@pmed.1003034.ref025]\]. Most other studies focused on the impact of single point-of-care biomarkers on antibiotic prescription. A large study in Vietnam showed a reduction of antibiotic use after CRP testing for non-severe acute RTIs in adults as well as in children \[[@pmed.1003034.ref026]\]. In the European ambulatory care setting, there is evidence that CRP testing can reduce immediate antibiotic prescription in children when appropriate guidance is provided to the healthcare professional \[[@pmed.1003034.ref027],[@pmed.1003034.ref028]\]. A randomised controlled trial from Switzerland studied PCT-guided treatment, but found no effect on antibiotic prescription rates \[[@pmed.1003034.ref029]\].

To our knowledge, this is the first multicentre randomised trial designed to measure the impact of a clinical decision rule on antibiotic prescription in children with suspected lower RTI in the ED. A major strength is that our trial studied the impact of a decision rule on usual care. Because the trial was conducted in different settings, mostly general hospitals, we believe our findings are generalisable to general paediatric practice. We had complete information on the outcome antibiotic prescription, good compliance to the protocol, a high follow-up rate, and sufficient power. The sensitivity analyses showed similar results as our primary analyses, confirming the robustness of our findings. There are also some limitations. Logistical problems in starting the trial in 2 hospitals resulted in a longer baseline period before rollout, potentially affecting the power of our study ([Fig 1](#pmed.1003034.g001){ref-type="fig"}). However, the sensitivity analysis truncating this prolonged baseline period gave results similar to our main analysis, so we believe our overall estimates are valid. Another limitation is the amount of missing Feverkidstool variables in the pre-intervention phase, especially CRP. This did not influence our primary analyses (as CRP was not needed in these models), but limited the number of included patients in the subgroup analyses, where the calculated risk of the Feverkidstool was required. This may have introduced some bias in the subgroup analyses. Next, not all eligible children could be included in the trial. Doctors in the ED often are under time pressure, leaving insufficient time or attention to recruit patients for a trial, as has been acknowledged by other paediatric ED trials \[[@pmed.1003034.ref005],[@pmed.1003034.ref023]\]. Comparison of the included and non-included children showed that severely ill children were included more frequently. This was the same in both phases of the study, and the rate of eligible children whose families declined participation was also stable over the study phases. Therefore, we believe there was no selection bias introduced by a lack of allocation concealment at the individual level. We believe that we did not miss any children with severe infections, so our results on strategy failure and complications are generalisable.

Although we could not prove an overall reduction of antibiotic prescription, our study implies that guiding antibiotic treatment by a decision rule based on the Feverkidstool is non-inferior in terms of safety in non-complex cases of suspected lower RTI. Moreover, patient outcomes may be improved by better targeting of antibiotics. Implementation of the decision rule in clinical practice would require measuring (point-of-care) CRP, which is not routinely done in all patients with fever and respiratory symptoms \[[@pmed.1003034.ref030]\]. However, we recommend a low threshold for CRP measurements and risk assessments for bacterial pneumonia in these children, and withholding antibiotics in children with a predicted risk of ≤10%, provided that careful safety-netting and good access to healthcare are in place \[[@pmed.1003034.ref031]\]. To avoid the risk of over-prescription in children with a predicted risk of \>10%, this approach should be closely monitored. Future research should focus on the safety of higher decision thresholds and on the impact in settings with higher antibiotic prescription rates at baseline, or with a larger proportion of low-risk children. Our observed 30% antibiotic prescription rate at baseline for suspected lower RTIs is lower than what has been described in other European EDs, where antibiotic prescription rates range from 52% to 78% \[[@pmed.1003034.ref005],[@pmed.1003034.ref006],[@pmed.1003034.ref013],[@pmed.1003034.ref032]\]. Even though the populations in many studies cannot be directly compared, a recent paper showed that after adjustment for differences in population, large variability in antibiotic prescription remains \[[@pmed.1003034.ref001]\]. We expect that the effect of our intervention on antibiotic prescription may therefore be larger in settings with a higher baseline prescription rate, or in populations with a larger proportion of low-risk children.

A clinical decision rule for childhood pneumonia did not reduce overall antibiotic prescription, but was non-inferior in terms of strategy failure. Exploratory analyses showed that the intervention reduced antibiotic prescriptions in low/intermediate-risk children, and that it reduced overall strategy failures, suggesting improved targeting of antibiotics by the decision rule.
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:   Netherlands Trial Register
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:   procalcitonin
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:   respiratory tract infection
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Refs need to be in square brackets in the main text and please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>

The start date for the trial / recruitment in your paper do not match the dates at the trial registration page provided. Please comment. Also there is a discrepancy between the number of registrants needed and how many were recruited (1100 / 900). Please provide more details (line 128) and also comment on whether the study is underpowered.
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Please provide a CONSORT checklist as a supp file, using sections and paragraph numbers instead of pages. Apologies if I have missed this.

Please remove the data statement text from the main Word doc -- it is automatically pulled in from the submission form.

Comments from the reviewers:

Reviewer \#1: This articles reports the results of a stepped-wedge trial assessing the impact of an intervention aimed at reducing antibiotics prescription in low-risk children with pneumonia. The trial includes 8 hospitals, sequentially randomised to the intervention. I have listed my comments below:

\* I was not able to visualise Figure S1 which was provided in .eps format

\* Sample size calculation (cf Lines 197-198): Please provide justification for not adjusting for multiple testing in the presence of two co-primary outcomes. I would also like to understand whether the significant results seen for the strategy failure outcome remain significant using a significance threshold of 2.5% (and a 97.5% confidence interval).

\* Please provide the assumptions made behind the statement \"The intra cluster correlation coefficient was unknown, but we assumed a power of 90% at independency would result in a power of 80% or more at multilevel analysis.\" Based on my experience, a loss of only 10% power between an independent and a cluster (stepped-wedge) trial seems somewhat unlikely. I understand that the ICC was unknown but I would like the authors to tell us what ICC was compatible with this minimal loss of power. In addition, given the observed ICC of 0.04, I would like to understand what power was attainable with the sample size and for the targeted difference.

\* There appears to be an inconsistency in the OR calculation for Antibiotic prescription. According to my raw calculation 101/402 vs 179/597 leads to an OR of 0.78 in favour of the intervention (or 1.28 using the intervention as the reference and not 1.06 as reported in Table 2). I understand that the unadjusted OR is in fact adjusted for the time period and that the OR estimated from the model is likely to be different from the one obtained via a simple calculation like mine; however, this seems like a big difference. Please confirm.

\* The odds ratios for antibiotic prescription and strategy failure (both \'bad\' outcomes) appear to be computed in different directions, i.e. once using the intervention period as the reference and once using the pre-intervention period as the reference. This is confusing and I would suggest using the pre-intervention as the reference for all estimates so that an odds ratio smaller than 1 always corresponds to an improvement with the intervention.

\* Please consider adding a figure showing the proportion of patients with antibiotic prescription for each period within each hospital so we can visualise the patterns over time.

\* Please provide the ICC for both co-primary endpoints in Table 2.

\* Please add p-values to Table 2 for at least the primary and secondary analyses.

\* In Table 2, please add a note to explain what the sensitivity analysis labelled \"population around roll-out period\" consist of.

\* Looking at the different components of the \"strategy failure\" outcome, it looks like the main differences are due to fever at Day 7 (and to a lesser extent, oxygen need at Day 7). I am not a clinical expert; however, it seems somewhat implausible to me that a strategy aimed at withdrawing antibiotics would help reduce fever at Day 7. In fact, my understanding was that the risk lied in the opposite direction. I therefore wonder whether this finding (a significant reduction in the proportion of patients experiencing strategy failure) might be due to chance and/or subject to some degree of bias. This needs to be explained/discussed in more details in the discussion.

\* Please explain why \"the data of patients included during the roll-out period\" are thought to \"carry most weight in the analyses\" (cf lines 363-364).

-Laurent Billot

Reviewer \#2: van de Maat and colleagues have submitted a manuscript utilizing a stepped-wedge cluster randomized trial to assess the impact of a clinical decision rule on suspected lower respiratory tract infection in children less than five years of age. Utilizing 999 children enrolled in this study, the decision rule did not impact antibiotic prescribing but did result in less strategy failure. An exploratory analysis among low and intermediate risk children did identify a reduction in antibiotic use and no difference in strategy failure.

Main concern:

The conclusion was that the clinical decision rule did not reduce overall antibiotic prescription and less strategy failures occurred during the intervention. This is an appropriate conclusion based on the data. However, the authors intervention and power calculation were based on antibiotics not being prescribed in low and intermediate risk children but high risk children were enrolled and included in the analysis. The trial ended up assessing the use of the clinical decision rule in all patients and since likely a significant portion were high risk the impact on antibiotic use was not observed.

Below are additional thoughts and criticism by section:

Title: The abstract and manuscript discuss decreasing antibiotics for lower respiratory tract infection and the title states pneumonia. While these are similar, I recommend a change from pneumonia to lower respiratory tract infection.

Abstract: Appropriate

Introduction:

1\. The objective of the study was to lower antibiotic use in low or intermediate risk children, however all risk categories were enrolled so the study tested the impact of the clinical decision rule on children presenting with potential LRTI. To address just low or intermediate risk, only these patients should have been enrolled.

Methods:

1\. What number was considered a fever? This was stated in the supplemental protocol. For the readers it would be helpful to have this listed.

2\. Page 7 line 136- What kind of otitis? Please be more specific as I\'m assuming this is otitis media.

3\. After the intervention was implemented did all patients have the clinical decision rule utilized or only in patients that an informed consent was obtained? When was the informed consent obtained, before or after the use of the calculator?

4\. Who performed the informed consent? Clinical coordinator, physician?

5\. What constitutes a patient being ill? Was this based on just a clinicians generally belief or were there specific factors that put a patient in the ill category?

Outcomes

1\. Were all antibiotics prescribed considered appropriate? If an antibiotic not recommended for pneumonia was prescribed were these patients excluded?

2\. Strategy failure was considered if an antibiotic was switched. If a patient had their antibiotic switched due to allergy or other adverse drug reaction was this considered a failure? Was the reason for switch documented?

3\. Strategy failure was also considered if a secondary hospitalization occurred. I assume this hospitalization had to be due to the same respiratory problem. The authors should specify this as some children could be hospitalized due to an unrelated problem.

4\. Complications included parapneumonic effusion or empyema. Was there a certain size of an effusion that had to be present on a chest Xray? Were any effusion on a chest Xray considered a parapneumonic effusion? This should be better specified though with so few complications this point is very minor.

Power calculation

1\. The power calculation was based on low and intermediate risk patients presenting with pneumonia though the study enrolled all patients.

2\. The interim analysis changed the needed patients based on more patients in the low risk category receiving antibiotics with the assumption that a greater decrease in antibiotics would be observed. How were the authors able to determine the number of patients in the low risk group if not all patients had the necessary items (eg. crp) to calculate the risk?

2\. The authors mention that this analysis could evaluate non-inferiority in terms of strategy failure. What was the non-inferiority margin that was going to be used to determine if non-inferiority was present? Furthermore, this non-inferiority analysis was not performed so is this even needed to be stated?

Results:

1\. What is the break down in the intervention period of the number of patients in the different risk categories? This could be included in the table and in the pre intervention period just report on those that a score could be calculated.

2\. What is included in \"demanding logistics?\" Does this include being discharged before the patient could be enrolled since these patients were not as sick as those in the trial.

3\. AS stated before \"ill appearance\" should be more clearly described since so many children are reported to be ill appearing. I would include this as a footnote in table 1.

4\. In table 1, the pre intervention type of antibiotics added up to 179. Did a patient receive 2?

5\. Table 2- in the complications both pre and post intervention have it stated as 0%. In this situation since there is 1 patient in each group a 0.x% would be appropriate.

6\. What percentage of the patients that would be considered high risk received antibiotics?

Discussion:

1\. The conclusion based on the data is fair but the study ended up including what were likely much more high risk patients in the study since all patient types were included which was not the objective of the study. I do realize a challenge was the lack of knowing the risk group in the pre-intervention phase.

2\. The authors state the lack of CRP did not influence the primary analysis however not being able to compare the risk categories and only do this as an exploratory analysis was not the objective and intent of the study and the intervention. This leads to a conclusion about the decision rule that potentially underestimates the interventions impact.

3\. The authors state that the primary aim was to evaluate the overall impact of a decision rule on antibiotic prescription and strategy failure. The authors stated objective was to \"safely reduce antibiotic prescription in children under five suspected of a lower RTI at the ED, by withholding antibiotics in children at low or intermediate risk of bacterial pneumonia, as predicted by the Feverkidstool.\" The authors should remove first sentence of the section \"Interpretation of results...\" and focus on what the main objective was. The results were more directed toward the overall impact and not those with just low or intermediate risk.

4\. The authors discuss low and intermediate risk patients but present limited data on the number of patients in each category.

Overall, this manuscript is interesting. The primary objective is not truly evaluated based on the patients enrolled and the results presented. Because of these results, the study did not substantially assess the hypothesis of using the decision rule to decrease antibiotic use, though it appears the decision rule has benefits in both reduction and strategy failures.

Reviewer \#3: This is an important study using a stepped-wedge cluster RCT design to evaluate an intervention to safely reduce antibiotic prescriptions. During the preintervention phase usual care is provided to childhood pneumonia patients in 8 hospitals in The Netherlands. This is followed by an intervention phase during which a validated clinical prediction model (clinical characteristics and C-reactive protein) is used to guide antibiotic prescription in children with uncomplicated pneumonia. The co-primary outcomes in the trial are antibiotic prescription rate and strategy failure comprising secondary antibiotic prescription or hospitalisation, persistent fever or oxygen dependency and complications.

1\. The abstract states that the trial could not be blinded and the same is repeated within the text in the method section without further elaboration as to why blinding could not be achieved. This statement on failure to implement blinding can be strengthened in the methods section of the manuscript by explaining why it was not possible to achieve blinding.

2\. The abstract reports that 8 clusters (hospitals) were allocated to sequences of treatment but does not report the number of hospitals randomised to each sequence of treatment and the number of sequences. Similarly, this information is not contained in the body of the manuscript.

3\. The introduction is well written with sufficient detail to justify the conduct of the study. It also contains the objectives for the trial but does not give a rationale for a stepped wedge design.

4\. The authors do not describe their attempts (if any) at allocation concealment. It is noteworthy that allocation concealment can be implemented even in situations where blinding is not feasible and that individual recruitment into cluster trials without concealment of allocation (or blinding) increases the risk of selection bias.

5\. More details are required about the randomisation, recruitment and assignment of clusters to allow the reader ascertain the risk of bias. The authors should provide more details about the statistician who generated the random sequence - independence of the statistician, knowledge of cluster identities, and any other role in the trial. Who recruited the clusters? Who assigned the clusters to the sequence?

6\. The trial has two co-primary outcomes: antibiotic prescription and strategy failure (that comprised five components - two of the five components i.e. secondary antibiotic prescription and hospitalisation are based on clinician judgment). The authors refer to antibiotic prescription outcome as a rate in the abstract, while in actual terms this is a proportion and not a rate. The authors overcome some of the difficulties associated with defining and reporting composite outcomes by providing a consistent definition of strategy failure in the abstract, methods and results. The authors also present data for all composite components useful for determining whether a similar effect occurred for all components of the composite. (Cordoba et al. BMJ 2010; 341:c3920 doi:10.1136/bmj.c3920) The following changes could further enhance the reporting of the composite outcome. Providing a rationale for the composite outcome including clinical importance of the components will help with interpretation of the results. At present the discussion and interpretation of the significant findings of reduction in strategy failure seem to ignore the fact that this was a composite outcome and that this outcome was mainly driven by secondary antibiotic prescription. Please refer to Cordoba 2010 on interpreting and discussing effects based on composite indicators.

7\. The authors are transparent in reporting the change in sample size calculations after the initial protocol. They also adopt a well described approach for calculating sample size in stepped wedge trials. The sample size calculation as reported is difficult to replicate because details on the number of clusters and clusters allocated at each sequence, cluster size, and ICC or coefficient of variation or assumptions made about these parameters are not presented in the sample size justification. Was an allowance for variation in cluster size made because from supplementary table 6 there was considerable variation in the final cluster sizes?

8\. The sample size justification contains the terms, interim analysis, risk reduction, superiority and non-inferiority. The aim of the study as stated in the introduction section was to safely reduce antibiotic prescription. The sample size calculation should be based on this aim and not to show superiority or non-inferiority as implied in the final sentences in the sample size justification. The authors should consider revising the use of the terms superiority and non-inferiority in their sample size justification, because retaining these terms in the sample size justification will require adopting a different approach to estimating sample size. In the absence of an intracluster correlation coefficient, I found the assumption that a power of 90% for independent data would equate to 80% power for correlated data to be a strong assumption that needs justification.

9\. The primary analysis in this paper is based on a multilevel logistic regression model clustered by eight hospitals and adjusting for time as a fixed effect. The correlation of observations in the clusters is accounted for by inclusion of the hospitals as random effects in the multilevel model. This is one of the recommended approaches for analysing intervention effect in stepped wedge studies. The analysis of stepped wedge trials using mixed effect models requires strong assumptions about correlation of observation within each cluster. These assumptions may be inappropriate when the number of clusters is small as is the case in the current study. (Thompson et al. Stats Med. 2018; 37(16) 2487-2500) The authors should explain the potential impact of the few clusters in the trial on the results obtained from analysis approach that is suited for analysis involving a large number of clusters.

10\. The sensitivity analysis section does not provide details on the type of imputation that was done for the first of the four sensitivity analyses apart from the statement that covariates with \>10% missing data were imputed. The second sensitivity analysis appear to be based on single imputation. The authors should consider commenting on the limitations of their approaches to imputing missing data.

11\. The multiple imputation assumed data were missing at random. A sensitivity analysis of departure from missing at random assumption will be helpful in assessing the robustness of the reported results following multiple imputation.

12\. The results are appropriately presented based on the analysis approach that was adopted and the recommendation for reporting contained in the CONSORT extension for stepped wedge cluster RCT. Results are presented for both intention-to-treat and per protocol analysis.

13\. The authors state in the discussion \"Clinical characteristics of children with missing Feverkidstool variables were comparable to those with complete information. This supports the assumption that missing data were at random, with no major bias to our subgroup analyses\". Based on literature on missing data, this is an untestable assumption because the data we would need to test it is missing (Carpenter & Kenward. 2013. Multiple imputation and its applications. John Wiley & Sons, UK)

14\. A more detailed discussion of the authors statement that they \"included severely ill children more frequently\" is warranted because this could point to selection bias.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003034.r002
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19 Dec 2019

Dear Dr. van de Maat,

Thank you very much for re-submitting your manuscript \"A clinical decision rule guiding antibiotic prescription in children suspected of lower respiratory tract infections in The Netherlands: a stepped-wedge, cluster randomized trial\" (PMEDICINE-D-19-03060R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and it was also seen again by three reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Dec 23 2019 11:59PM.

Sincerely,

Louise Gaynor-Brook, MBBS PhD

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

General comments: Please put reference brackets before the full stop (or any punctuation), and after a space at the end of the word/sentence.

Please revise your title according to PLOS Medicine\'s style. We suggest \"Evaluation of a clinical decision rule to guide antibiotic prescription in children suspected of lower respiratory tract infections in The Netherlands: a stepped-wedge, cluster randomized trial\"

Data Availability: Thank you for providing a link to the repository and a point of contact (not an author) for data access. Please explain the reasons for restricting data access to between 12 months and 10 years after publication. PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available at the time of article publication, provided it is legal and ethical to do so. Please confirm that data will be made available at the time of publication, and not at 12 months following publication.

Abstract Background: Please expand upon the context of why the study is important.

Abstract Methods and Findings:

Please include more detail on the setting (e.g. EDs in cities in the Netherlands; types of hospital).

Line 54 - please clarify what constitutes 'usual care' e.g. according to what clinical guidelines

Please provide the number of children included in each group (based on the sequence of treatment available at the ED visited)

Please add a sentence to the abstract to mention the two complications quoted around line 390.

In the last sentence of the Abstract Methods and Findings section, please add " potentially affecting the power of our study" with relation to the longer baseline period.

Please begin your Abstract Conclusions with \"In this study, we observed \...\" or similar.

Line 76 - please revise both instances of 'less' to 'fewer'

Author Summary:

Line 88 - please revise 'part' to 'number'

Line 98 - please revise both instances of 'less' to 'fewer'; please consider another term for 'failed the initial treatment'

Line 102 - please replace 'First of all, this means that...' with 'We observed that'

Methods:

Please provide more justification in the Methods (as you have in your rebuttal letter) for the adjustment to sample size from 1100 to 900 children.

Line 162 - Please cite the supplementary file containing your CONSORT checklist.

Line 169 - Please include more detail on the setting (e.g. EDs in cities in the Netherlands).

Line 194 - Please clarify what constitutes 'usual care' e.g. according to clinical/local guidelines?

Line 211 - please define APLS

Line 261 - please amend to Supplementary File S1

Line 337 - please revise 'less' to 'fewer'

Tables 2 & 3 - When a p value is given, please specify the statistical test used to determine it in the legend.

Table S5 - Please specify the statistical test used to determine statistical significance

Discussion

Please remove all subheadings from within the Discussion i.e. 'principal findings' and so on

Please reorganize the Discussion as follows: a short, clear summary of the article\'s findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Protocol

Supplementary Files 1 and 2 correspond to the final protocol and original protocol respectively. Please amend.

References:

Please ensure all journal titles are appropriately formatted and capitalised e.g. BMJ \[ref 20\]

CONSORT statement - please format the final column of your checklist as some information appears to have been lost in the .pdf file provided. Please provide section and paragraph numbers.

Comments from Reviewers:

Reviewer \#1: All my comments are addressed.

-Laurent Billot

Reviewer \#2: The authors have thoroughly addressed my reviewer comments. I applaud the authors for the detail and time spent in responding to my concerns. I still have 2 thoughts for consideration

1\. The authors\' state on page 5 line 118, \"The absence of a gold standard for bacterial pneumonia impedes deciding upon appropriate treatment.\" I disagree with this statement. While the true gold standard for diagnosing pneumonia would be sampling the lung, this will never be done for many important reasons. However, the common pathogens to cause community-acquired pneumonia in the age-group studied (eg. Streptococcus pneumoniae) provide us the ability to make determinations of which antibiotics are inappropriate in the population included in this study. The guideline referenced in the response to the reviewers provide recommendations for antibiotics in the outpatient setting. For example, it would be inappropriate to prescribe a quinolone and/or azithromycin. Some experts would suggest prescribing cefdinir for pneumonia would also be inappropriate. Regardless, I think the authors\' goal of reducing total antibiotic prescribing is important and they should just note that appropriateness of the antibiotic was not determined.

2\. Is the strategy failure within 7 days of starting or completing the antibiotic? I think it is from starting the antibiotic based on other statements in the manuscript but I think it would be helpful for the reader to have it listed in the outcome paragraph.

3\. The authors should specifically state in the outcomes that changing of antibiotics due to adverse drug reaction was considered a treatment failure.

4\. The authors reported that they did non inferiority but I did not see the non-inferiority margin of 5% listed in the statistical analysis portion of the manuscript.

I believe the effort of these authors in conducting this trial, reporting the results, and addressing the reviewer comments are outstanding. While no study is perfect, I do believe the authors have significantly improved the manuscript and should be published.

Jason Newland

Reviewer \#3: The authors have responded adequately to most of the comments raised in the review. The following specific comments need to be addressed further:

1\) What was the basis for assuming that 90% power under independence equates to 80% power in a scenario of non independence? THis qustion was not addressed in the authors\' responses.

2\) Will the figure that contains the range of ICCs used in the sample size calculation (provided in response to reviewer\'s comments) be included in the final manuscript? If not then it will be useful to write these ranges in the sample size section to allow readers to independently replicate the sample size calculation. I reckon that although the ICC is unknown these ranges were used as plausible estimates. If they are not provided then a reader cannot follow the sample size calculation.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003034.r004
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6 Jan 2020

Dear Mrs. van de Maat,

On behalf of my colleagues and the academic editor, Dr. Jason Newland, I am delighted to inform you that your manuscript entitled \"Evaluation of a clinical decision rule to guide antibiotic prescription in children suspected of lower respiratory tract infections in The Netherlands: a stepped-wedge, cluster randomized trial\" (PMEDICINE-D-19-03060R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Louise Gaynor-Brook, MBBS PhD

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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